The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study

• Published in: BMC research notes Vol. 6; no. 1; p. 453
• Main Authors: Ohkura, Tsuyoshi, Inoue, Kazuoki, Fujioka, Youhei, Nakanishi, Risa, Shiochi, Hideki, Sumi, Keisuke, Yamamoto, Naoya, Matsuzawa, Kazuhiko, Izawa, Shoichiro, Ohkura, Hiroko, Kato, Masahiko, Yamamoto, Kazuhiro, Taniguchi, Shin-ichi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.11.2013; BioMed Central
• Subjects: Aged; Blood Glucose - metabolism; Body mass index; C-Peptide - blood; Care and treatment; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes therapy; Fasting; Female; Glimepiride; Glucose; Health aspects; Humans; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - blood; Insulin resistance; Isoindoles - therapeutic use; Male; Middle Aged; Molecular Targeted Therapy; Postprandial Period; Proinsulin; Proinsulin - blood; Sulfonylurea Compounds - therapeutic use; Triglycerides - blood; Type 2 diabetes; Japan
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/1756-0500-6-453

An elevated PI/I ratio is attributable to increased secretory demand on β-cells. However, the effect of postprandial targeting therapy on proinsulin level is unknown. We evaluated the metabolic effect of glinide and sulfonylurea (SU) using the meal tolerance test (MTT). MTT was applied to previously untreated Type 2 Diabetes Mellitus (T2DM) subjects. Twenty-two participants were given a test meal (450 kcal). Plasma glucose and insulin were measured at 0 (fasting), 30, 60, 120, and 180 min. Serum proinsulin and C-peptide immunoreactivity (CPR) were measured at 0 and 120 min. Postprandial profile was assessed at baseline and following 3 months treatment with either mitiglinide or glimepiride. Plasma glucose level at 30, 60, 120, and 180 min was significantly improved by mitiglinide. Whereas, glimepiride showed a significant improve plasma glucose at 0, 180 min. Peak IRI shifted from 120 to 30 min by mitiglinide treatment. The pattern of insulin secretion was not changed by glimepiride treatment. Whereas mitiglinide did not affect the PI/I ratio, glimepiride tended to increase the PI/I ratio. Moreover, although mitiglinide did not affect PI/I ratio as a whole, marked reduction was noted in some patients treated by mitiglinide. PI/I ratio was reduced significantly in the responder group. The responder subgroup exhibited less insulin resistance and higher insulinogenic index at baseline than non-responders. Moreover, the triglyceride level of responders was significantly lower than that of non-responders. Mitiglinide improved postprandial insulin secretion pattern and thereby suppressed postprandial glucose spike. In T2DM patients with low insulin resistance and low triglyceride, mitiglinide recovered impaired β-cell function from the viewpoint of the PI/I ratio. UMIN000010467.